HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 111 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2013. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $22,620,778 | +245.5% | 432,024 | +168.4% | 0.01% | +200.0% |
Q1 2024 | $6,547,610 | +9.9% | 160,954 | -0.1% | 0.00% | 0.0% |
Q4 2023 | $5,957,212 | -1.0% | 161,180 | +2.3% | 0.00% | -33.3% |
Q3 2023 | $6,017,915 | -52.9% | 157,537 | -52.9% | 0.00% | -50.0% |
Q2 2023 | $12,778,681 | 0.0% | 334,608 | 0.0% | 0.01% | 0.0% |
Q1 2023 | $12,778,681 | -56.7% | 334,608 | -35.5% | 0.01% | -60.0% |
Q4 2022 | $29,501,455 | -99.9% | 518,479 | -0.3% | 0.02% | +25.0% |
Q3 2022 | $20,558,863,000 | +164.2% | 519,951 | +194.0% | 0.01% | +200.0% |
Q2 2022 | $7,782,016,000 | +16.5% | 176,864 | +5.6% | 0.00% | +33.3% |
Q1 2022 | $6,678,504,000 | +10.1% | 167,465 | +11.0% | 0.00% | +50.0% |
Q4 2021 | $6,066,403,000 | +0.9% | 150,868 | +2.1% | 0.00% | 0.0% |
Q3 2021 | $6,009,982,000 | -14.8% | 147,738 | -4.9% | 0.00% | -33.3% |
Q2 2021 | $7,051,947,000 | +11.9% | 155,295 | +2.8% | 0.00% | 0.0% |
Q1 2021 | $6,299,442,000 | -4.3% | 151,102 | -2.0% | 0.00% | 0.0% |
Q4 2020 | $6,584,901,000 | +77.5% | 154,177 | +9.2% | 0.00% | +50.0% |
Q3 2020 | $3,710,736,000 | -4.8% | 141,200 | -2.9% | 0.00% | 0.0% |
Q2 2020 | $3,897,958,000 | -75.2% | 145,392 | -83.3% | 0.00% | -81.8% |
Q1 2020 | $15,708,723,000 | -16.3% | 873,192 | -17.5% | 0.01% | 0.0% |
Q4 2019 | $18,764,172,000 | +36.1% | 1,058,329 | +19.1% | 0.01% | +22.2% |
Q3 2019 | $13,787,429,000 | +586.3% | 888,938 | +660.2% | 0.01% | +800.0% |
Q2 2019 | $2,008,909,000 | +24.6% | 116,933 | +16.8% | 0.00% | 0.0% |
Q1 2019 | $1,612,400,000 | +18.3% | 100,149 | +7.5% | 0.00% | 0.0% |
Q4 2018 | $1,362,770,000 | -15.9% | 93,149 | +4.5% | 0.00% | 0.0% |
Q3 2018 | $1,620,127,000 | +6.8% | 89,165 | -0.8% | 0.00% | 0.0% |
Q2 2018 | $1,516,681,000 | -10.8% | 89,904 | +3.5% | 0.00% | 0.0% |
Q1 2018 | $1,701,176,000 | -0.4% | 86,839 | +3.0% | 0.00% | 0.0% |
Q4 2017 | $1,708,344,000 | +25.7% | 84,321 | +7.7% | 0.00% | 0.0% |
Q3 2017 | $1,359,515,000 | +23.5% | 78,268 | -8.9% | 0.00% | 0.0% |
Q2 2017 | $1,100,943,000 | +25.3% | 85,877 | +26.6% | 0.00% | 0.0% |
Q1 2017 | $878,986,000 | +119816.2% | 67,823 | -8.6% | 0.00% | 0.0% |
Q4 2016 | $733,000 | -38.8% | 74,238 | -25.1% | 0.00% | 0.0% |
Q3 2016 | $1,198,000 | +43.0% | 99,172 | +2.2% | 0.00% | 0.0% |
Q2 2016 | $838,000 | -25.8% | 97,027 | -18.7% | 0.00% | 0.0% |
Q1 2016 | $1,129,000 | -48.4% | 119,279 | -5.5% | 0.00% | -50.0% |
Q4 2015 | $2,186,000 | +47.1% | 126,193 | +14.0% | 0.00% | 0.0% |
Q3 2015 | $1,486,000 | -28.8% | 110,686 | +19.7% | 0.00% | 0.0% |
Q2 2015 | $2,087,000 | +261.1% | 92,461 | +128.3% | 0.00% | +100.0% |
Q1 2015 | $578,000 | +55.8% | 40,496 | +5.5% | 0.00% | – |
Q4 2014 | $371,000 | +17.0% | 38,396 | +10.3% | 0.00% | – |
Q3 2014 | $317,000 | -5.7% | 34,796 | +2.4% | 0.00% | – |
Q2 2014 | $336,000 | -22.2% | 33,996 | 0.0% | 0.00% | – |
Q1 2014 | $432,000 | -15.3% | 33,996 | 0.0% | 0.00% | -100.0% |
Q4 2013 | $510,000 | -16.0% | 33,996 | -38.2% | 0.00% | 0.0% |
Q3 2013 | $607,000 | -78.8% | 54,996 | -84.8% | 0.00% | -75.0% |
Q2 2013 | $2,867,000 | – | 361,188 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 14,092,771 | $206,177,000 | 28.12% |
BB BIOTECH AG | 8,322,860 | $121,763,000 | 3.90% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 398,633 | $4,579,000 | 2.84% |
DOHENY ASSET MANAGEMENT /CA | 227,193 | $3,324,000 | 2.43% |
SNYDER CAPITAL MANAGEMENT L P | 2,833,759 | $41,458,000 | 2.24% |
First Light Asset Management, LLC | 938,399 | $13,729,000 | 2.19% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 9,027,164 | $132,067,000 | 1.77% |
Taylor Wealth Management Partners | 204,277 | $2,989,000 | 1.72% |
Sterling Global Strategies LLC | 22,000 | $321,860,000 | 1.63% |
Granite Investment Partners, LLC | 988,939 | $14,468,000 | 1.06% |